WINDTREE THERAPEUTICS INC (WINT)       0.38  +0 (+0.26%)

0.38  +0 (+0.26%)

US97382D3035 - Common Stock - After market: 0.38 0 (0%)

WINDTREE THERAPEUTICS INC0.38

NASDAQ:WINT (8/16/2022, 7:06:36 PM)+0 (+0.26%)

After market: 0.38 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-03 2022-08-03 Earnings (Next) 11-08 2022-11-08
Ins Owners N/A Inst Owners 5.08%
Market Cap 11.17M Shares 29.41M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 87.5
IPO 08-09 1995-08-09

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

WINT Daily chart

Company Profile

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company, which engages in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 33 full-time employees. The Company’s development programs are primarily focused on the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Its Cardiovascular Program’s products candidates include Istaroxime, Oral SERCA2a Activators and Rostafuroxin. Its Pulmonary Program’s product candidates include Lyophilized KL4 Surfactant and AEROSURF (aerosolized KL4 surfactant based on ADS technology). The Company’s lead product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients with acute heart failure (AHF) with a potentially differentiated safety profile from existing treatments. Istaroxime demonstrated significant improvement in both diastolic and systolic aspects of cardiac function and is under phase II clinical trials.

Company Info

WINDTREE THERAPEUTICS INC

2600 Kelly Rd Ste 100

Warrington PENNSYLVANIA 18976

P: 12154889300.0

CEO: Craig E. Fraser

Employees: 33

Website: http://www.windtreetx.com/

News

News Image2 months ago - Windtree TherapeuticsWindtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value

Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa., June 29, 2022 (GLOBE NEWSWIRE)...

News Image3 months ago - Windtree TherapeuticsWindtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid

The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better...

News Image4 months ago - Windtree TherapeuticsWindtree Therapeutics Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure Conference

Company to host conference call following the presentation...

News Image5 months ago - Windtree TherapeuticsWindtree to Participate in the Lytham Partners Spring 2022 Investor Conference

Company to present on Monday, April 4, 2022 at 11:00 am...

News Image5 months ago - Windtree TherapeuticsWindtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple...

WINT Twits

Here you can normally see the latest stock twits on WINT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example